Oncology and Therapy

237 papers and 1.9k indexed citations i.

About

The 237 papers published in Oncology and Therapy in the last decades have received a total of 1.9k indexed citations. Papers published in Oncology and Therapy usually cover Oncology (139 papers), Pulmonary and Respiratory Medicine (82 papers) and Molecular Biology (41 papers) specifically the topics of Lung Cancer Treatments and Mutations (30 papers), Cancer Immunotherapy and Biomarkers (21 papers) and Cancer Genomics and Diagnostics (17 papers). The most active scholars publishing in Oncology and Therapy are Peter Schmid, Mark R. Nathan, Xavier Thomas, Christopher R. Heery, Kwok‐Leung Cheung, Idan Cohen, Khaled Khazim, Raphael E. Pollock, John H. Howard and Adouda Adjiri.

In The Last Decade

Fields of papers published in Oncology and Therapy

Since Specialization
EngineeringComputer SciencePhysics and AstronomyMathematicsEarth and Planetary SciencesEnergyEnvironmental ScienceMaterials ScienceChemical EngineeringChemistryAgricultural and Biological SciencesVeterinaryDecision SciencesArts and HumanitiesBusiness, Management and AccountingSocial SciencesPsychologyEconomics, Econometrics and FinanceHealth ProfessionsDentistryMedicineBiochemistry, Genetics and Molecular BiologyNeuroscienceNursingImmunology and MicrobiologyPharmacology, Toxicology and Pharmaceutics

This network shows the specialization of papers published in Oncology and Therapy. Nodes represent fields, and links connect fields that are likely to share authors.

Countries where authors publish in Oncology and Therapy

Since Specialization
Total citations of papers

This map shows the geographic distribution of research published in Oncology and Therapy. It shows the number of citations received by papers published by authors working in each country. You can also color the map by specialization and compare the number of papers published in Oncology and Therapy with the expected number of papers based on a country's size and research output (numbers larger than one mean the country's share of papers is larger than expected).

Rankless by CCL
2025